Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STOCKWATCH: Waiting for the biotech bubble to burst

This article was originally published in Scrip

Executive Summary

Everybody's wondering, when will the biotech bubble burst? Whilst there have been IPOs cancelled citing "market conditions", news of many more primary and secondary offerings continues to appear in our in boxes. Logic dictates that the bubble will burst eventually and indeed in the last year we've already had two warning pops caused by drug pricing concerns, but the NASDAQ Biotech Index has continued its relentless climb. Even so, fresh evidence is appearing that the bubble is about to die, starting with this latest earnings season

You may also be interested in...



J.P. Morgan Stockwatch: No Substitute For M&A

Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.

 

Stockwatch: Hopes For Fireworks But Expectations For Goldilocks

With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.

Time Is Money: Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?

Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027894

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel